| Literature DB >> 22182502 |
Kate E Killick1, John A Browne, Stephen D E Park, David A Magee, Irene Martin, Kieran G Meade, Stephen V Gordon, Eamonn Gormley, Cliona O'Farrelly, Karsten Hokamp, David E MacHugh.
Abstract
BACKGROUND: Mycobacterium bovis is the causative agent of bovine tuberculosis (BTB), a pathological infection with significant economic impact. Recent studies have highlighted the role of functional genomics to better understand the molecular mechanisms governing the host immune response to M. bovis infection. Furthermore, these studies may enable the identification of novel transcriptional markers of BTB that can augment current diagnostic tests and surveillance programmes. In the present study, we have analysed the transcriptome of peripheral blood leukocytes (PBL) from eight M. bovis-infected and eight control non-infected age-matched and sex-matched Holstein-Friesian cattle using the Affymetrix® GeneChip® Bovine Genome Array with 24,072 gene probe sets representing more than 23,000 gene transcripts.Entities:
Mesh:
Year: 2011 PMID: 22182502 PMCID: PMC3292584 DOI: 10.1186/1471-2164-12-611
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Mean leukocyte cell population subset counts in control and . Error bars represent the standard error for each mean cell count estimate.
Figure 2Hierarchical clustering dendrogram generated using the complete gene expression profiles for the . The dendrogram was generated from the complete gene expression dataset for each animal using the Euclidean distance metric. The division between the BTB and control animal groups was supported by a bootstrap value of 100%.
Gene expression fold-changes between M.bovis-infected (n = 8) and control (n = 8) based on microarray and real time qRT-PCR analyses
| Gene symbol | Gene name | Gene description | Mean | Mean | Real time qRT-PCR |
|---|---|---|---|---|---|
| Caspase 1 gene | A member of the cysteine-aspartic acid protease. Plays a role in the cell apoptosis | -1.45 | -1.98 | 0.001 | |
| Cluster of differentiation 83 gene | A cell surface protein found in antigen presenting cells. Believed to play a role in antigen presentation or the cellular interactions that follow lymphocyte activation | +4.92 | +5.88 | < 0.001 | |
| Cytotoxic T-lymphocyte-associated protein 4 gene | A member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells | +3.20 | +3.46 | 0.001 | |
| Beta-defensin 10 gene | Host defence response to bacterial infection; has antimicrobial activity | -3.38 | -12.21 | 0.018 | |
| interferon, beta 1, fibroblast | Cytokine activity | Not DE | Not DE | > 0.05 | |
| Interferon (alpha, beta and omega) receptor 1 gene | A type I membrane protein that forms one of the two chains of a receptor for interferons alpha and beta | Not DE | -2.20 | < 0.001 | |
| Interferon gamma gene | A soluble cytokine with antiviral, immunoregulatory and anti-tumor properties. A potent activator of macrophages | Not DE | Not DE | > 0.05 | |
| Interferon gamma receptor 1 gene | Forms a heterodimer with interferon gamma receptor 2. Involved in binding of interferon gamma | Not DE | +2.23 | < 0.001 | |
| Interferon gamma receptor 2 gene | Forms a heterodimer with interferon gamma receptor 1. Involved in binding of interferon gamma | -1.32 | Not DE | > 0.05 | |
| Interleukin 1, alpha gene | A member of the interleukin 1 cytokine family produced by macrophages. Involved in various immune responses, inflammatory processes, and haematopoiesis | +1.89 | +2.47 | 0.009 | |
| Interleukin 8 gene | A chemokine that mediates the inflammatory response | +2.15 | +4.01 | < 0.002 | |
| Interleukin 15 gene | A cytokine that regulates T and natural killer cell activation and proliferation | -1.49 | -2.03 | < 0.001 | |
| Janus kinase 1 gene | A widely expressed membrane-associated phosphoprotein involved in the interferon-alpha/beta and -gamma signal transduction pathways | Not DE | Not DE | > 0.05 | |
| Killer cell immunoglobulin-like receptor, three domains, short cytoplasmic tail, 1 | A transmembrane glycoprotein expressed by natural killer cells and some T cells. Involved in regulation of the immune response | -1.44 | -2.63 | 0.005 | |
| myeloid differentiation primary response gene (88) | A cytosolic adapter protein that functions as a signal transducer in the interleukin-1 and Toll-like receptor signalling pathways | -1.31 | -2.55 | < 0.001 | |
| protein tyrosine phosphatase, non-receptor type 2 gene | A member of the protein tyrosine phosphatase (PTP) family that is involved in a variety of cellular processes including cell growth, and differentiation | Not DE | -1.43 | < 0.001 | |
| signal transducer and activator of transcription 1, 91kDa gene | A transcriptional activator protein activated in response to cytokines and growth factors | +1.28 | -1.27 | < 0.001 | |
| signal transducer and activator of transcription 2, 113kDa gene | A transcriptional activator protein activated in response to cytokines and growth factors | -1.23 | -1.86 | < 0.001 | |
| Toll-like receptor 3 gene | An intracellular pathogen recognition receptor (PRR) that largely recognises viral pathogen-associated molecular patterns (PAMPs). Mediates the production of cytokines necessary for the development of effective immunity | -1.55 | -1.63 | 0.001 | |
| Toll-like receptor 4 gene | A cell-surface PRR that recognises PAMPs expressed by infectious agents. Mediates the production of cytokines necessary for the development of effective immunity | +2.41 | Not DE | > 0.05 | |
| Triggering receptor expressed on myeloid cells 1 gene | A receptor expressed on myeloid cells upon microbial infection. Amplifies neutrophil and monocyte-mediated inflammatory responses stimulating release of pro-inflammatory chemokines and cytokines | -1.70 | -2.81 | 0.002 | |
| Tyrosine kinase 2 gene | A member of the tyrosine kinase. A component of both interferon signalling pathways | Not represented on array | -1.60 | < 0.001 | |
| TYRO protein tyrosine kinase binding protein gene | A transmembrane protein involved in cell signalling | -1.38 | -1.98 | < 0.001 | |
Gene descriptions taken from GeneCards version 3 [82] and the NCBI Entrez Gene database [83]. For the microarray data, genes with fold-change differences in expression were significant after adjustment for multiple testing using the Benjamini-Hochberg method [31] (adjusted P ≤ 0.05). 'Not DE' indicates a gene was not differentially expressed between the two sample groups.
Gene ontology (GO) categories identified using IPA
| Gene ontology category | Number of genes | |
|---|---|---|
| Inflammatory response | 1.66 × 10-11 - 1.64 × 10-2 | 241 |
| Cellular development | 8.95 × 10-10 - 1.57 × 10-2 | 308 |
| Cellular growth and proliferation | 1.65 × 10-9 - 1.57 × 10-2 | 333 |
| Haematological system development and function | 1.65 × 10-9 - 1.64 × 10-2 | 279 |
| Haematopoiesis | 2.60 × 10-8 - 1.57 × 10-2 | 173 |
| Tissue morphology | 1.78 × 10-7 - 1.19 × 10-2 | 114 |
| Cellular function and maintenance | 5.44 × 10-7 - 1.65 ×10-2 | 138 |
| Cell death | 9.57 × 10-7 - 1.60 × 10-2 | 419 |
| Cell-mediated immune response | 1.06 × 10-6 - 1.25 × 10-2 | 109 |
| Connective tissue disorders | 1.72 × 10-6 - 5.94 × 10-3 | 234 |
| Immunological disease | 1.72 × 10-6 - 1.57 × 10-2 | 344 |
| Inflammatory disease | 1.72 × 10-6 - 1.28 × 10-2 | 364 |
| Skeletal and muscular disorders | 1.72 × 10-6 - 1.22 × 10-2 | 235 |
| Infectious disease | 1.82 × 10-6 - 1.17 × 10-2 | 223 |
| Cell-to-cell signalling and interaction | 8.33 × 10-6 - 1.64 × 10-2 | 210 |
| Dermatological diseases and conditions | 1.04 × 10-5 - 1.57 × 10-2 | 107 |
| Free radical scavenging | 1.23 × 10-5 - 1.23 × 10-5 | 14 |
| Molecular transport | 1.23 × 10-5 - 7.43 × 10-3 | 86 |
| Cell signalling | 2.40 × 10-5 - 7.21 × 10-5 | 133 |
| Respiratory disease | 2.86 × 10-5 - 1.24 × 10-2 | 109 |
| Cellular compromise | 3.09 × 10-5 - 1.57 × 10-2 | 41 |
| Genetic disorder | 3.39 × 10-5 - 1.64 × 10-2 | 104 |
| Immune cell trafficking | 3.51 × 10-5 - 1.64 × 10-2 | 163 |
| Humoral immune response | 5.08 × 10-5 - 1.19 × 10-2 | 78 |
| Organismal injury and abnormalities | 9.51 × 10-5 - 1.05 × 10-2 | 81 |
| Tissue development | 1.19 × 10-4 - 1.05 × 10-2 | 108 |
| Haematological disease | 1.78 × 10-4 - 1.35 × 10-2 | 162 |
| Gastrointestinal disease | 1.88 × 10-4 - 5.51 × 10-3 | 42 |
| Hepatic system disease | 1.88 × 10-4 - 1.64 × 10-2 | 89 |
| Lymphoid tissue structure and development | 1.94 × 10-4 - 5.94 × 10-3 | 5 |
| Antigen presentation | 3.42 × 10-4 -1.64 × 10-2 | 83 |
| Cellular movement | 3.58 × 10-4 - 1.63 × 10-2 | 157 |
| Vitamin and mineral metabolism | 3.59 × 10-4 - 7.21 × 10-3 | 74 |
| Antimicrobial response | 3.92 × 10-4 - 1.28 × 10-2 | 32 |
| Hypersensitivity response | 5.86 × 10-4 - 8.60 × 10-3 | 31 |
| Infection mechanism | 9.89 × 10-4 - 1.57 × 10-2 | 39 |
| Gene expression | 1.07 × 10-3 - 1.57 × 10-2 | 254 |
| Hair and skin development and function | 1.23 × 10-3 - 1.57 × 10-2 | 22 |
| Post-translational modification | 2.27 × 10-3 - 9.78 × 10-3 | 84 |
| Cancer | 2.51 × 10-3 - 1.57 × 10-2 | 385 |
| Endocrine system development and function | 2.65 × 10-3 - 2.65 × 10-3 | 21 |
| Carbohydrate metabolism | 3.77 × 10-3 - 3.77 × 10-3 | 6 |
| Cell morphology | 3.77 × 10-3 - 1.28 × 10-2 | 23 |
| Lipid metabolism | 3.77 × 10-3 - 7.43 × 10-3 | 17 |
| Neurological disease | 3.77 × 10-3 - 1.47 × 10-2 | 49 |
| Small molecule biochemistry | 3.77 × 10-3 - 7.43 × 10-3 | 23 |
| Metabolic disease | 3.91 × 10-3 - 3.91 × 10-3 | 7 |
| Embryonic development | 4.59 × 10-3 - 1.57 × 10-2 | 21 |
| Nervous system development and function | 4.59 × 10-5 - 1.18 × 10-2 | 8 |
| Reproductive system disease | 5.84 × 10-3 - 7.54 × 10-3 | 79 |
| Cell cycle | 5.94 × 10-3 - 1.18 × 10-2 | 20 |
| Endocrine system disorders | 5.94 × 10-3 - 5.94 × 10-3 | 3 |
| Opthalmic disease | 5.94 × 10-3 - 6.60 × 10-3 | 7 |
| RNA post-transcriptional modification | 6.04 × 10-3 - 6.04 × 10-3 | 13 |
| Cardiovascular system development and function | 6.68 × 10-3 - 1.30 ×10-2 | 19 |
| Cell assembly and modification | 6.68 × 10-3 - 1.28 × 10-2 | 14 |
| Organ development | 6.68 × 10-3 - 1.19 × 10-2 | 6 |
| Renal and urological system development and function | 1.18 × 10-2 - 1.30 × 10-2 | 11 |
| Reproductive system development and function | 1.18 × 10-2 - 1.18 × 10-2 | 4 |
The top ranking GO categories identified by IPA are listed according to P-values. P-value ranges are based on subcategory P-values within each parent term.
Figure 3Sub-categories of the top ranking IPA-identified . The numbers of genes displaying increased and decreased relative expression for affects immune response, the top ranking subcategory, are shown. The number of differentially expressed genes within each functional subcategory is indicated.
Top-ranking canonical pathways identified using IPA
| Canonical Pathway Name | Ratio | |
|---|---|---|
| Natural killer cell signalling | 3.06 × 10-4 | 23/112 (0.205) |
| Communication between innate and adaptive immune cells | 4.11 × 10-4 | 17/89 (0.191) |
| TREM1 signalling | 2.20 × 10-3 | 15/69 (0.217) |
| Dendritic cell maturation | 4.96 × 10-3 | 29/174 (0.167) |
| Cysteine metabolism | 7.43 × 10-3 | 9/90 (0.100) |
| JAK/STAT signalling | 8.22 × 10-3 | 15/64 (0.234) |
| NRF2-mediated oxidative stress response | 8.98 × 10-3 | 35/183 (0.191) |
| T cell receptor signalling | 1.08 × 10-2 | 20/107 (0.187) |
| IL6 signalling | 1.52 × 10-2 | 20/93 (0.215) |
| CCR5 signalling in macrophages | 1.84 × 10-2 | 16/92 (0.174) |
| Chemokine signalling | 1.92 × 10-2 | 15/75 (0.200) |
| Calcium-induced T-lymphocyte apoptosis | 2.07 × 10-2 | 12/66 (0.182) |
| IL-17 signalling | 2.21 × 10-2 | 16/74 (0.216) |
| Prolactin signalling | 2.21 × 10-2 | 16/75 (0.213) |
| Synaptic long term potentiation | 2.22 × 10-2 | 19/113 (0.168) |
| Toll-like receptor signalling | 2.63 × 10-2 | 11/54 (0.204) |
| FLT3 signalling in hematopoietic progenitor cells | 2.77 × 10-2 | 15/74 (0.203) |
| Systemic lupus erythematosus signalling | 2.81 × 10-2 | 20/151 (0.132) |
| Renin angiotensin signalling | 3.01 × 10-2 | 21/120 (0.175) |
| Phospholipase C signalling | 3.28 × 10-2 | 39/253 (0.154) |
| Oncostatin M signalling | 3.36 × 10-2 | 9/35 (0.257) |
| Thyroid cancer signalling | 3.36 × 10-2 | 9/42 (0.214) |
| B cell receptor signalling | 3.72 × 10-2 | 25/154 (0.162) |
| Interferon signalling | 3.97 × 10-2 | 6/30 (0.200) |
| Production of nitric oxide and reactive oxygen species in macrophages | 4.13 × 10-2 | 28/185 (0.151) |
| NF-κB signalling | 4.17 × 10-2 | 25/152 (0.164) |
| Notch signalling | 4.29 × 10-2 | 8/43 (0.186) |
| IL10 signalling | 4.36 × 10-2 | 13/70 (0.186) |
| P38 MAPK signalling | 4.57 × 10-2 | 17/97 (0.175) |
| Role of NFAT in regulation of the immune response | 4.70 × 10-2 | 29/196 (0.148) |
| Parkinson's signalling | 5.00 × 10-2 | 5/17 (0.294) |
The top ranking canonical pathways identified by IPA are listed according to P-values. The ratio indicates the number of differentially expressed genes involved in each canonical pathway divided by the total number of genes within each pathway as per the IPA Knowledge Base.
Figure 4Differential gene expression in the TLR signalling pathway. Genes within the TLR signalling pathway showing differential expression are highlighted in colour. Colour intensity indicates the degree of increased (red) or decreased (green) relative expression in the BTB group compared to the control animal group. A white colour indicates genes that were not differentially expressed and entities coloured grey represent microbial PAMPs.